CSL (AU:CSL) has released an update. CSL Limited’s CEO, Dr. Paul McKenzie, has adjusted his holdings in the company’s securities following shareholder approval at the recent Annual General Meeting. He ...

Amid the drama at the biotech, a new figure has stepped up right as the company needs a new long-term chief executive and ...

CSL Ltd (ASX: CSL) will report its 2026 half-year financial results this morning. The update comes as the company prepares for a change in senior leadership. Just after market close on Tuesday, CSL ...

The CSL Ltd (ASX: CSL) share price is in focus today after the company delivered a 90-day interim CEO review and financial update, revealing revised, lower FY26 earnings guidance and plans for around ...

Interim CSL chief executive Gordon Naylor has urged investors to keep faith in the group’s fundamentals, earnings and outlook despite a record-setting $6.9bn impairment and a sharp share-price slump, ...

CSL has slashed its revenue projection for the fiscal year from $15.8 billion to $15.2 billion, in another indication of the Australian company’s financial distress since its ill-fated 2022 ...

SYDNEY--Shares of pharmaceutical company CSL fell early Wednesday as investors react to the sudden departure of chief executive Paul McKenzie and an 80% fall in first-half net profit. The stock was ...

CSL has recorded one of the ASX’s biggest-ever impairments at $6.9bn, yet its interim boss insists it remains a “great company”. He said it “was still a great company” as angry investors on Monday ...